Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products

Wed Jan 30, 2013 4:27am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130130:nPn1302865


LONDON,  January 30, 2013  /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, discusses Sunesis
Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc.

The pharmaceutical sector is a very lucrative and competitive industry. And for
emerging growth companies, it is difficult to make a meaningful impact in this
cutthroat industry.

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced
cancer drug development organization committed to advancing its lead product
candidate, Vosaroxin, to improve the lives of people with cancer.

Sunesis Pharmaceuticals' work translates to a rosy top line as demonstrated by
the  $25 million  it earned from a previously announced royalty purchase
agreement with Royalty Pharma. It took possession of  $15 million  from the
second tranche of a 2011 venture loan facility. It raised  $17.3 million  from
the sale of 3.6 million shares of common stock and  $1.4 million  from the gross
exercise of 0.6 million warrants to purchase common stock. This not only shows
that Sunesis is able to raise capital for research purposes, but it also
represents the company's keen interest in creating shareholder value.

The company is in the follow-up stage of trials of Vosaroxin, having completed a
Phase 2 trial in ovarian cancer patients in 2010. However, broader market
tailwinds will propel the company through the next decade. Vosaroxin is a
first-in-class anticancer quinolone derivative, a class of compounds that has
not been used previously for the treatment of cancer.  As of now, notable
breakthroughs are being made with the drug, particularly as complete remissions
have been observed in patients treated with Vosaroxin in combination with
Cytarabine.

Just like its bigger competitors, Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences
Inc. (NASDAQ: GILD), Sunesis also wants to make a big impact. To ensure this, it
has entered into a collaboration agreement with Millennium Pharmaceuticals for
the development of Sunesis' inhibitor. It also announced the license of the
company's LFA-1 inhibitor program to SARcode Corporation, a privately held
bio-pharmaceutical company. In addition, it has announced a collaboration
agreement with Biogen Idec Inc. (NASDAQ: BIIB) to discover, develop, and
commercialize inhibitors of Raf kinase and up to five additional oncology kinase
targets.

All these developments will signal the market's gravitation toward Sunesis
products. Considering that ovarian cancer is the eighth most common cancer among
women, it would be accurate to say that vosaroxin will be relevant in the
market. In addition, the future promise of FDA approval brightens the long-term
picture and promises longevity. With a market capitalization of  $226 million 
and a 52-week range  $1.29 - $6.85  (the stock is currently trading close to its
high at around  $4), it would be accurate to say that Sunesis Pharmaceuticals
will gain tremendous value in the next few years.

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out
our referral form here: 
http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial reporters,
writers and bloggers in the business, EmergingGrowth.com is emerging as a
leading digital financial media portal. Its services provide users, subscribers
and advertisers with a variety of content and tools through a range of online,
social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other
financial media companies with its sly approach to reading between the lines in
order to locate that needle in the haystack.  Sign up today to see what
EmergingGrowth.com has to offer.

Join our LinkedIn Group… 
http://www.linkedin.com/groups/?gid=4650356&trk=hb_side_g

Like us on Facebook... 
http://www.facebook.com/pages/EmergingGrowthcom/474647062557938

Disclosure

All information contained herein as well as on the  EmergingGrowth.com  website
is obtained from sources believed to be reliable but not guaranteed to be
accurate or all-inclusive. All material is for informational purposes only, is
only the opinion of EmergingGrowth.com and should not be construed as an offer
or solicitation to buy or sell securities. In addition, Please make sure you
read and understand the  Terms of Use,  Privacy Policy  and the  Disclosure 
posted on the  EmergingGrowth.com  website. Always remember that investing in
securities such as the ones listed within are for high-risk tolerant individuals
only and not the general public. Whether you are an experienced investor or not,
you should always consult with a stockbroker, financial advisor, or similar
before purchasing or selling any securities viewed on any emails sent from 
EmergingGrowth.com  or its website.

SOURCE  EmergingGrowth.com


Contact: EmergingGrowth.com, info@EmergingGrowth.com, +1-305-323-5687

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.